Oz CPA - Scisparc CEO CFO
| SPRC Stock | USD 0.24 0.01 4.00% |
Insider
Oz CPA is CEO CFO of Scisparc
| Age | 37 |
| Address | Tower A, Tel Aviv, Israel, 6971916 |
| Phone | 972 7 334 47180 |
| Web | https://scisparc.com |
Scisparc Management Efficiency
The company has return on total asset (ROA) of (0.3885) % which means that it has lost $0.3885 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8591) %, meaning that it created substantial loss on money invested by shareholders. Scisparc's management efficiency ratios could be used to measure how well Scisparc manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.67. In addition to that, Return On Capital Employed is expected to decline to -0.63. At present, Scisparc's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 2.7 M, whereas Other Assets are forecasted to decline to about 14.5 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| David MD | Nuvation Bio | 54 | |
| Sumita JD | Instil Bio | 50 | |
| Jane Springer | Hoth Therapeutics | 39 | |
| Stacy Markel | Nuvation Bio | 59 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Sandeep MD | Instil Bio | 55 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Gary Hattersley | Nuvation Bio | 57 | |
| W Vernon | Nuvation Bio | 65 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Nicole White | Assembly Biosciences | N/A | |
| AO FRACP | Assembly Biosciences | 65 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Uri MD | Assembly Biosciences | 52 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| James Foster | Virax Biolabs Group | 39 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Timothy Moore | Instil Bio | 63 | |
| Michelle Doig | Nuvation Bio | 46 | |
Management Performance
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.39 |
Scisparc Management Team
Elected by the shareholders, the Scisparc's board of directors comprises two types of representatives: Scisparc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scisparc. The board's role is to monitor Scisparc's management team and ensure that shareholders' interests are well served. Scisparc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scisparc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oz CPA, CEO CFO | ||
| Itschak Shrem, President Director | ||
| Adi ZuloffShani, Chief Officer |
Scisparc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Scisparc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (4.20) % | ||||
| Current Valuation | 13.53 K | ||||
| Shares Outstanding | 10.36 M | ||||
| Shares Owned By Institutions | 1.70 % | ||||
| Number Of Shares Shorted | 391.84 K | ||||
| Price To Book | 0.36 X | ||||
| Price To Sales | 1.44 X | ||||
| Revenue | 2.88 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Scisparc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scisparc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scisparc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scisparc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scisparc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Scisparc Stock refer to our How to Trade Scisparc Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scisparc. If investors know Scisparc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scisparc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.28) | Revenue Per Share 1.357 | Quarterly Revenue Growth (0.57) | Return On Assets (0.39) | Return On Equity (0.86) |
The market value of Scisparc is measured differently than its book value, which is the value of Scisparc that is recorded on the company's balance sheet. Investors also form their own opinion of Scisparc's value that differs from its market value or its book value, called intrinsic value, which is Scisparc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scisparc's market value can be influenced by many factors that don't directly affect Scisparc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scisparc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scisparc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scisparc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.